<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694068</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002027</org_study_id>
    <nct_id>NCT02694068</nct_id>
  </id_info>
  <brief_title>Biological Determinants of Peritoneal Dialysis</brief_title>
  <acronym>Bio-PD</acronym>
  <official_title>Biological Determinants of Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal Dialysis (PD) is a technique for treating kidney failure where fluid is instilled&#xD;
      into the body's peritoneal cavity. Fluid and solutes travel across the peritoneal membrane,&#xD;
      and the function of this membrane is critical to successful PD. Studies have shown that&#xD;
      certain demographic and clinical variables explain a very small part of the variability in&#xD;
      baseline function. This study will further explore the common genetic variants that determine&#xD;
      the baseline peritoneal membrane function in patients starting treatment with PD and change&#xD;
      in function upon treatment .&#xD;
&#xD;
      This study will incorporate data from subjects' first ever peritoneal equilibrium test (PET),&#xD;
      changes in the transfer of water across the peritoneal membrane over time, demographic&#xD;
      information, and results from laboratory analysis of DNA, blood, and dialysate. The&#xD;
      investigators hope that this study will provide information on the biological pathways that&#xD;
      account for variability in the peritoneal membrane. This could ultimately lead to the&#xD;
      development of biomarkers to identifying individuals at risk for decline in peritoneal&#xD;
      membrane function over time and/or be used to identify novel therapeutic targets to preserve&#xD;
      or enhance membrane function. Identifying the biological pathways will also increase the&#xD;
      understanding of vascular biology, angiogenesis, and fibrosis that could be applied to other&#xD;
      tissues and other diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will comprise of patient populations from pre-existing biorepositories and&#xD;
      prospectively enrolled subjects. DNA will be analyzed from cohorts with data and DNA already&#xD;
      collected and available, while prospective sites will collect plasma, DNA, and spent&#xD;
      dialysate for further analysis. Clinical data related to the subjects' first ever Peritoneal&#xD;
      Equilibrium Test (PET), demographic information, change in ultrafiltration capacity over&#xD;
      time, will be correlated with various genetic markers of interest.&#xD;
&#xD;
      Blood and dialysate will be collected at the first study visit, and there will be no&#xD;
      additional sample collection. These samples will be collected as part of a PET during a&#xD;
      standard of care study visit, or during a timed 4 hour dwell of 2.5% or 4.25% dextrose&#xD;
      solution. Annually, subjects will either undergo a PET as standard of care or perform an&#xD;
      additional 4 hour dwell as part of the study. These subsequent measures will be utilized to&#xD;
      determine change in ultrafiltration capacity over time.&#xD;
&#xD;
      This study has two specific aims:&#xD;
&#xD;
      Aim 1: To identify and validate genetic loci that influence the peritoneal solute transfer&#xD;
      rate (PSTR) at start of PD.&#xD;
&#xD;
      Aim 2: To identify and validate genetic loci in pre-specified biologic pathways with change&#xD;
      in peritoneal ultrafiltration capacity.&#xD;
&#xD;
      If subjects grant permission, Genome Wide Association Studies (GWAS) results may be&#xD;
      transferred to the NIH database of genotypes and phenotypes (dbGaP). Additionally, subjects&#xD;
      may agree that remaining samples will be maintained at the University of Washington Kidney&#xD;
      Research Institute in a repository for use in future research studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2015</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Four-hour Dialysate to Plasma ratio of creatinine</measure>
    <time_frame>Prior to study participation or within 6 months of enrollment</time_frame>
    <description>From Peritoneal Equilibration Test performed at the time of start of PD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peritoneal ultrafiltration capacity over time</measure>
    <time_frame>Once per year (up to 3 years)</time_frame>
    <description>This will be determined from annual assessments of the peritoneal ultrafiltration capacity with a four-hour timed dwell with 4.25%/2.5% dextrose.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">4865</enrollment>
  <condition>End-Stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Discovery for Aim One</arm_group_label>
    <description>2173 subjects will be involved in the discovery cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Replication for Aim One</arm_group_label>
    <description>1673 subjects will comprise the replication cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discovery for Aim Two</arm_group_label>
    <description>824 subjects will be involved in the discovery cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Replication for Aim Two</arm_group_label>
    <description>538 subjects will comprise the replication cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peritoneal Equilibrium Test</intervention_name>
    <description>These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.</description>
    <arm_group_label>Discovery for Aim One</arm_group_label>
    <arm_group_label>Discovery for Aim Two</arm_group_label>
    <arm_group_label>Replication for Aim One</arm_group_label>
    <arm_group_label>Replication for Aim Two</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4 hour dwell of 2.5/4.25% dextrose solution</intervention_name>
    <description>If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.</description>
    <arm_group_label>Discovery for Aim One</arm_group_label>
    <arm_group_label>Discovery for Aim Two</arm_group_label>
    <arm_group_label>Replication for Aim One</arm_group_label>
    <arm_group_label>Replication for Aim Two</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Dialysate, and DNA may be collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults undergoing maintenance Peritoneal Dialysis therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 20 who are able to provide consent&#xD;
&#xD;
          -  Record of a PET within 6 months of starting PD treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Rajnish Mehrotra</investigator_full_name>
    <investigator_title>Dr. Rajnish Mehrotra, MD. Professor of Medicine, Division of Nephrology, University of Washington</investigator_title>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Genetic</keyword>
  <keyword>Peritoneal Membrane</keyword>
  <keyword>Peritoneal Equilibrium Test</keyword>
  <keyword>Ultrafiltration Capacity</keyword>
  <keyword>End Stage Renal Disease (ESRD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

